Experimental AATD drug study halted early
NCT ID NCT06677307
First seen Dec 29, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study tested a new drug called KRRO 110 in healthy volunteers and people with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The goal was to check safety and how the drug moves through the body. The study was stopped early, and results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AATD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
-
New Zealand Clinical Research
Christchurch, New Zealand
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
St. Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
-
The Prince Charles Hospital
Brisbane, Queensland, 4032, Australia
Conditions
Explore the condition pages connected to this study.